Clinical trials: Cancer of the Esophagus
Esophagus Cancer, Esophageal Cancer
Proton Beam Therapy in the Treatment of Esophageal Cancer
The investigators plan to include both operable and inoperable patients with esophagus cancer in this prospective trial. Since both proton and photon treatments are biologically equivalent, the investigators do not expect a…
- Conditions
- Esophagus Cancer, Esophageal Cancer, Cancer of the Esophagus
- Trial name
- NCT03482791
- Testing
- Proton beam therapy, Patient-Reported Outcome Measures
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Washington University School of Medicine
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) with or without nivolumab to the effect of modified fluorouracil, leucovorin calcium, and…
- Conditions
- Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT05677490
- Testing
- Fluorouracil, Leucovorin Calcium, Oxaliplatin
- Where
- 798 sites in United States, Puerto Rico
- Volunteers
- 382 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
The purpose of this study is to evaluate the safety and efficacy of Pumitamig in combination with chemotherapy versus Nivolumab in combination with chemotherapy in participants with previously untreated advanced or metastatic…
- Trial name
- NCT07221149
- Testing
- Pumitamig, Folfox, Capox
- Where
- 161 sites in United States, Argentina and 18 more
- Volunteers
- 690 people
- Sponsor
- Bristol-Myers Squibb
Esophageal Adenocarcinoma
Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma
The goal of this trial is to learn if adding consolidative chemotherapy to routine chemoradiation can better control both local recurrence and metastasis and reduce the need for surgical intervention.
- Trial name
- TNT Esophagus (NCT07603375)
- Testing
- FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Solid Tumor Malignancies, Hematologic Cancer
The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
The purpose of this study is to explore the effectiveness of 18F-G1 PET/CT in patients with solid tumors and hematological malignancies receiving immunotherapy
- Conditions
- Solid Tumor Malignancies, Hematologic Cancer, Lung Cancer, Esophagus Cancer
- Trial name
- NCT07039474
- Testing
- 18F-G1
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine…
- Conditions
- NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus
- Trial name
- NCT07277413
- Testing
- IDE892, IDE397
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- IDEAYA Biosciences
Gastric Cancer, Gastro-esophageal Junction Cancer
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with…
- Conditions
- Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT06005493
- Testing
- AZD5863, AZD2936
- Where
- 25 sites in United States, China and 6 more
- Volunteers
- 392 people
- Sponsor
- AstraZeneca
Lung Non-Small Cell Carcinoma, GastroEsophageal Cancer
Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy
This study assesses for early signs of damage to the heart following chest radiation therapy using both imaging (cardiac magnetic resonance imaging and cardiac positron emission tomography) and changes in blood biomarkers.
- Conditions
- Lung Non-Small Cell Carcinoma, GastroEsophageal Cancer, Esophagus Cancer
- Trial name
- NCT05717998
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging of the Heart
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Esophageal Cancer, Esophagus Cancer
Endoluminal Vacuum Therapy to Prevent Anastomotic Leakage After Esophagectomy Due to Esophageal Cancer
A prospective, multi-centre, exploratory and observational one-arm study to evaluate preventive Endoluminal Vacuum Therapy(pEVT) to prevent anastomotic leakage after esophagectomy due to esophageal cancer.
- Conditions
- Esophageal Cancer, Esophagus Cancer, Anastomotic Leak
- Trial name
- ESPY (NCT06097078)
- Testing
- Eso-SPONGE®
- Where
- Spain
- Volunteers
- 44 people
- Sponsor
- Aesculap AG
Cancer of Pancreas, Cancer of Stomach
Wet Heparinized Suction for Abdominal Cancer
The purpose of this research is to compare the amount and quality of tissue obtained by EUS-FNB when the device is flushed with an anticoagulant or "blood thinner" vs.
- Conditions
- Cancer of Pancreas, Cancer of Stomach, Cancer of Esophagus, Cancer of Liver
- Trial name
- EUS Heparin (NCT05041335)
- Testing
- wet heparinzed suction, Microsieve, No heparin flush
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
KRAS G12D Mutation, Advanced Solid Cancer
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation.
- Trial name
- NCT07023731
- Testing
- ARV-806
- Where
- 14 sites in United States
- Volunteers
- 76 people
- Sponsor
- Arvinas Inc.
Oesophageal Cancer, Oesophageal Adenocarcinoma
Evaluation of Seismocardiography(SCG) for Assessing Fitness and Predicting Outcomes in Oesophageal Cancer Surgery
Oesophageal cancer is a common cause of cancer death worldwide. Curative treatment involves chemotherapy and surgery but has significant risks.
- Conditions
- Oesophageal Cancer, Oesophageal Adenocarcinoma, Prehabilitation, Oesophagectomy
- Trial name
- SEISMIC (NCT07159711)
- Testing
- Seismofit
- Where
- 4 sites in United Kingdom
- Volunteers
- 164 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Esophageal Cancer, Advanced Esophageal Cancer
A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to find out whether adding the drug 2141-V11 to standard treatment (anti-PD-1 immunotherapy with or without 5-FU) is a safe treatment approach for participants with advanced esophageal, gastric, or…
- Conditions
- Esophageal Cancer, Advanced Esophageal Cancer, Gastric Cancer, Advanced Gastric Cancer
- Trial name
- NCT07818018
- Testing
- Intratumoral 2141-V11, Nivolumab, Fluoropyrimidine
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastric Cancer, Esophagogastric Junction Cancer
A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma
The purpose of this study is to evaluate the efficacy and safety of ONO-4578 in combination nivolumab and chemotherapy in participants with advanced or metastatic gastric cancer, esophagogastric junction cancer, or esophageal…
- Conditions
- Gastric Cancer, Esophagogastric Junction Cancer, Esophageal Adenocarcinoma
- Trial name
- NCT07818070
- Testing
- ONO-4578, Nivolumab, Oxaliplatin
- Volunteers
- 600 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Colorectal Cancer, Liver Cancer
Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Gastro-intestinal Cancer Patients
ACUPOX is a multicenter, open label, 2-cohort based phase II clinical study evaluating the interest of a standardized protocol of verum acupuncture in treatment of Oxaliplatin-induced peripheral neuropathy in patients with…
- Conditions
- Colorectal Cancer, Liver Cancer, Gastric Cancer, Pancreas Cancer
- Trial name
- ACUPOX (NCT05850130)
- Testing
- Acupuncture intervention, No acupuncture
- Where
- 15 sites in France
- Volunteers
- 182 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
This randomized phase II trial studies how well paclitaxel with or without cixutumumab works in treating patients with esophageal cancer or gastroesophageal junction cancer that has spread to other places in the body…
- Conditions
- Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Adenocarcinoma
- Trial name
- NCT01142388
- Testing
- Cixutumumab, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 232 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer, Esophagus Cancer
Retrospective Review of Esophageal Cancer at MSKCC
Residual tumor at the proximal or distal margin after esophagectomy is a known prognostic factor for poor survival outcomes in patients with esophageal cancer; however, the significance of the circumferential resection margin…
- Trial name
- NCT05706558
- Testing
- Esophagectomy
- Where
- United States
- Volunteers
- 4,000 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Upper Gastrointestinal Tract Adenocarcinoma
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
This randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) monoclonal antibody domvanalimab, the anti programmed cell…
- Trial name
- STAR-221 (NCT05568095)
- Testing
- Domvanalimab, Zimberelimab, Capecitabine
- Where
- 168 sites in United States, Argentina and 27 more
- Volunteers
- 1,040 people
- Sponsor
- Arcus Biosciences, Inc.
Advanced Solid Tumor, Metastatic Solid Tumor
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
This clinical study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of IDP-001 in participants with advanced or metastatic squamous and non-squamous NSCLC and other squamous cell…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
- Trial name
- NCT07602842
- Testing
- IDP-001
- Where
- 6 sites in United States
- Volunteers
- 132 people
- Sponsor
- InduPro, Inc.
Gastro-esophageal Junction (GEJ) Cancer, Esophagus Cancer
Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer
The goal of this clinical trial is to learn the safety of the addition of PULSAR radiation to standard of care chemotherapy and immunotherapy in people with esophageal and gastroesophageal junction cancer and to determine the…
- Trial name
- NCT07700420
- Testing
- PULSAR- Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy, FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)(D)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Texas Southwestern Medical Center